Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Showing matches for the individual search terms you entered. To search for an exact phrase, enclose your query in quotes.
Advanced filters
Search the full archive
Keyword matches

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (252 Online Views)

N. Sgherza1, E. Antonioli2, E. Zamagni3|4, C. Conticello5, F. Fazio6, S. Palmieri7, A. Cagnetta8, G. Palumbo9, A.G. Solimando10, R. Della Pepa11, C. Germano12, G. Palazzo13, C. De Risi14, A. Quinto15, G. Buda16, M. Gentile17|18, O. Annibali19, D. De Novellis20, P. Curci1, O. Battisti1, L. Pavan21|22, M. Capriata6, G. Di Carlo13, G. Proietti6, V. Del Fabro23, A.P. Falcone24, R. Spadano25, D. Derudas26, G. Mele27, G. Barilà28, M.T. Petrucci6, F. Di Raimondo5|29, F. Albano1|30, P. Musto1|30

1 Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
2 Hematology Unit, Careggi University Hospital, Firenze, Italy
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli", Italy
4 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
5 Division of Hematology and Stem Cell Transplantation, Policlinico“G. Rodolico-San Marco”, Catania, Italy
6 Department of Translational and Precision Medicine Hematology, Sapienza University, Roma, Italy
7 Hematology Unit, Ospedale Cardarelli, Napoli, Italy
8 Hematology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
9 Hematology Unit, AOU Policlinico Riuniti di Foggia, Italy
10 G. Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Italy
11 Department of Clinical Medicine and Surgery, University Federico II, Napoli,Italy
12 Hematology Unit,“Mons. Dimiccoli” Hospital, Barletta, Italy
13 Hematology Unit, “G. Moscati” Hospital, Taranto, Italy
14 Haematology and Transplant Unit, “V. Fazzi” Hospital, Lecce, Italy
15 Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”, Bari, Italy
16 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
17 Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Italy
18 Department of Pharmacy, Health and Nutritional Science, University of Calabria, Italy
19 Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Biomedico di Roma, Italy
20 Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy
21 Department of Medicine
22 (DIMED), Hematology section, Padua University School of Medicine, Italy
23 Faculty of Medicine and Surgery “Kore”, University of Enna, Italy
24 Department of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
25 Hematology Unit, Santo Spirito Hospital, Pescara, Italy
26 Department of Hematology, Businco Hospital, Cagliari, Italy
27 Hematology Unit,“A. Perrino” Hospital, Brindisi, Italy
28 Hematology Unit, Ospedale San Bortolo, Vicenza, Italy
29 Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, Italy
30 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy
Multiple Myeloma ODISSEY study Clinical Features
Title matches

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (350 Online Views)

E. Zamagni1, B. Dhakal2, S. Iida3, M.H. Sidiqi4|5, S.S. Yoon6, N. Callander7, C. Touzeau8|9|10|11, Q. Li12, A. Balogh12, A. Slaughter12, N. Benachour12, C. Lonardi12, A. Ghosh12, M. Vogel12, N. Lendvai12, T. Lengil12, M. Koneru13, N. Patel13, O. Costa Filho13, V. Mahajan13, J. Martínez-López14, K. Yong15, K. Weisel16, X. Leleu17

1 University of Bologna, Italy
2 Medical College of Wisconsin, Milwaukee, USA
3 Nagoya City University, Japan
4 Fiona Stanley Hospital, Perth, Australia
5 Curtin University, Perth, Australia
6 Seoul National University, Korea
7 University of Wisconsin, Madison, USA
8 Centre Hospitalier Universitaire Hotel Dieu, Nantes, France
9 Université d’Angers, Nantes, France
10 Université de Nantes, France
11 French Ministry of Health, Nantes, France
12 Johnson & Johnson
13 Legend Biotech USA Inc, Somerset, USA
14 Complutense University, Madrid, Spain
15 University College London, UK
16 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
17 CHU Poitiers, France
Multiple Myeloma CARTITUDE-4

P60 | TRIAL IN PROGRESS, MoMMent-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (326 Online Views)

K. Weisel1, E. Kastritis2, E. Gonzalez-Garcia3, S. Gentili4, C. Renner5, P. Ferraz6, N. Francella7, S. Sitar7, J. Buyze7, N. Healy7, N.M. Suñé7, P. Moreau8, M.V. Mateos9

1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 National and Kapodistrian University of Athens, Greece
3 University Hospital Cabueñes, Gijón, Spain
4 UOSD Ematologia Civitanova Marche AST Macerata, Civitanova Marche, Italy
5 Klinik Hirslanden, Zurich, Switzerland
6 Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal
7 Johnson & Johnson Innovative Medicine
8 Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France
9 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
LocoMMotion Trial MoMMent Trial Real-world Practice

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (369 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (336 Online Views)

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab

P44 | EARLIER USE OF CILTACABTAGENE AUTOLEUCEL IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT FROM THE CARTITUDE-4 STUDY (314 Online Views)

N.W.C.J. Van De Donk1, S. Parekh2, K. Li3, Y. Lin4, T.G. Martin5, S. Han2, R. Montes De Oca2, M. Suraneni3, M. Gormley2, B. Hodkinson2, J. Yuan2, F. Wang3, A. Kumar2, D. Yin2, D. Smirnov2, J. Patel2, N. Lendvai3, D. Madduri3, J. Zhu6, M. Koneru6, N. Patel6, D. Geng6, V. Plaks2, S. Harrison7|8|9

1 Vrije Universiteit Amsterdam, The Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, USA
3 Johnson & Johnson
4 Mayo Clinic, Rochester, USA
5 University of California San Francisco, USA
6 Legend Biotech USA Inc, Somerset, USA
7 Peter MacCallum Cancer Centre, Melbourne, Australia
8 Royal Melbourne Hospital, Australia
9 University of Melbourne, Parkville, Australia
CARTITUDE-4 Prognostic Biomarkers RRMM

P29 | PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY (230 Online Views)

M. Biglietto1, R. Mormile1, A. Piciocchi1, F. Fazio1, M. Capriata1, S. Sorella1, B. Mandelli1, D. Kasmi1, E. Baldacci1, A. Chistolini1, M.T. Petrucci1, C. Santoro1

1 Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
Multiple Myeloma Platelet Functions NDMM

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (303 Online Views)

R. Popat1, N.W.C.J. Van De Donk2|3, B. Faiman4, J. Yuda5, K. Kim6, A. Costa7, A. Laheij2|3, R.L. Doty8, J. Omel9, B. Lipe10, L. Sanchez11, A. Chari12, A. Lin13, H. Sroussi14, M. Fernandez15, K.S. Gray15, G. Aguilar15, K. Bolyard15, J. Schultz15, K. Qi15, D. Cortes-Selva15, J. Zhang15, C. Heuck15, K. Hawks15, K. Tian15, M. França15, L. Rasche16

1 University College London Hospitals NHS Foundation Trust, UK
2 Amsterdam University Medical Center, The Netherlands
3 Vrije Universiteit Amsterdam, The Netherlands
4 Cleveland Clinic, USA
5 National Cancer Center Hospital East, Kashiwa, Japan
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 D’or Institute for Research and Education, São Paulo, Brazil
8 University of Pennsylvania Smell and Taste Center, Philadelphia, USA
9 The Central Nebraska Myeloma Support Group, Grand Island, USA
10 University of Rochester Medical Center, USA
11 Icahn School of Medicine at Mount Sinai, New York, USA
12 University of California, San Francisco, USA
13 University of Pennsylvania, Philadelphia, USA
14 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA
15 Johnson & Johnson
16 University Hospital of Würzburg, Germany
TALISMAN study Multiple Myeloma RRMM

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (209 Online Views)

M. Puppi1|2|3, M. Pennisi4, F. Monaco5, L. Paris6, S. Aquino7, F. Ciceri8, M.C. Goldaniga9, M. Musso10, G. Buda11, M. Martino12, P. Chiusolo13, F. Fazio14, R. Mina15, F. Patriarca16, M.C. Tisi17, P. Tacchetti1, V. Marasco4, F. Ardizzoia1|2|3, M. Talarico1|2|3, K. Mancuso1|2|3, E. Maffini1, C. Carniti4, C. Terragna1, E. Zamagni1|2|3, F. Bonifazi1, M. Cavo2|3, P. Corradini4

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences
3 (DIMEC), University of Bologna, Italy
4 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
5 AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy
6 ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy
7 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy
11 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy
12 Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
14 Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy
15 AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
16 Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
17 Hematology Unit, San Bortolo Hospital, Vicenza, Italy
RRMM GIMEMA CAR-T

P23 | DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH COMPLETE REIMISSION AND MINIMAL RESIDUAL DISEASE NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK IN 228 PATIENTS (267 Online Views)

V. Venanzi1, S. Ciofini1, E. Antonioli2, G. Buda3, E. Bestoso1, D. Raspadori1, V. Candi4, L. Pengue2, M.L. Del Giudice3, A. Caremani4, S. Moretti5, G. Fontanelli5, I. Attucci2, M. T. Pirrotta5, C. Biagiotti5, S. Birtolo5, S. Grammatico5, S. Pilerci6, L. Notarfranchi7, G. Tancredi3, S. Galimberti3, M. Bocchia1, A. Gozzetti1

1 Department of Medicine Surgery and Neuroscience, Hematology, University of Siena, Italy
2 Department of Hematology, Careggi Hospital and University of Florence, Italy
3 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
4 Hematology Unit,Ospedale S. Donato, Arezzo, Italy
5 USL Toscana Centro, SOC Oncoematologia, Italy
6 Hematology Ospedale della Versilia, Lucca, Italy
7 Hematology Massa Carrara, Italy
CASSIOPEIA Trial Multiple Myeloma Tuscan network DARA-VTD

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (375 Online Views)

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (304 Online Views)

E. Lebel1, A. Abdulgawad2, S. Bramanti3, G. Garate4, P.J. Ho5, M. Keränen6, Y. Cohen7, M. Vase8, A. Khot9, I. Kristensen10, R. Leblanc11, C. Lee12, W. Legiec13, H. Magen14, M.V. Mateos15, D. Oh16, L. Pour17, N. Schutz18, A. Spyridonidis19, K. Weisel20, J. Zaucha21, S. Larson22, A. Varshavsky-Yanovsky23, K. Grazioli24, D. Basudhar24, H. Hu24, Y. Meng24, L. Eldjerou24, S. Bal25, S. Harrison9, R. Popat26, M. Raab27, P. Rodriguez-Otero28

1 Hadassah Medical Center, Jerusalem, Israel
2 Christie NHS Foundation Trust, Manchester, UK
3 IRCCS Istituto Clinico Humanitas, Rozzano, Italy
4 Hospital Aleman, Buenos Aires, Argentina
5 Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia
6 Helsinki University Hospital, Finland
7 Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel
8 Aarhus Universitetshospital, Midtjylland, Denmark
9 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
10 Odense Universitetshospital, Denmark
11 Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada
12 Royal Adelaide Hospital, Australia
13 St. John of Dukla Oncology Center of Lublin Land,Poland
14 Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel
15 Hospital Universitario de Salamanca, Spain
16 Monash Health and Monash University, Clayton, Victoria, Australia
17 Masaryk University and University Hospital Brno, Czech Republic
18 Hospital Italiano de Buenos Aires, Argentina
19 University Hospital of Patras, Greece
20 University Medical Center Hamburg-Eppendorf, Germany
21 Medical University of Gdańsk and University Clinical Center, Poland
22 UCLA Medical Center, Los Angeles, USA
23 Fox Chase Cancer Center Temple Health, Philadelphia, USA
24 Bristol Myers Squibb, Princeton, USA
25 University of Alabama at Birmingham, USA
26 University College London Hospital, UK
27 Universitaetsklinikum Heidelberg, Germany
28 Clinica Universidad de Navarra, Pamplona, Spain
QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (325 Online Views)

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM

P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP (304 Online Views)

E. Terpos1, E. Kastritis1, S. Delimpasi2, K. Papathanasiou3, V. Labropoulou4, N. Kanellias1, I.N. Stathopoulos1, M. Migkou1, E. Solia1, F. Theodorakakou1, E.E. Papaiakovou1, M. Kotsopoulou5, E. Katodritou6, M. Gavriatopoulou1, M.A. Dimopoulos1|7

1 National and Kapodistrian University of Athens, Greece
2 Evangelismos Hospital, Athens, Greece
3 University of Ioannina, Greece
4 University of Patras, Medical School, Greece
5 Metaxa Cancer Hospital,Piraeus, Greece
6 Theagenio Cancer Hospital, Thessaloniki, Greece
7 Korea University, Seoul, South Korea
Greek Myeloma Study Group NDMM Isa-VRd

P71 | DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOSIS: A PORTUGUESE MULTICENTER REAL-WORLD STUDY (270 Online Views)

R. Bergantim1, A. Roque2, J. Vieira3, G. Ferreira4, P. Martins Almeida3, P. Ferraz5, J. G. Freitas6, M. Neves7, E. Aguiar1, M. Lopes8, H. Martins3, F. Trigo1, C. Geraldes2, C. João7

1 ULS São João, Porto, Portugal
2 ULS Coimbra, Portugal
3 ULS Santa Maria, Lisboa, Portugal
4 ULS Aveiro, Portugal
5 ULS TMAD, Vila Real, Portugal
6 ULS Braga, Portugal
7 Fundação Champalimaud, Lisboa, Portugal
8 ULS EDV, Santa Maria da Feira, Portugal
AL amyloidosis Multiple Myeloma Real-world Study
Text matches

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (244 Online Views)

First match: ... daptation, and survival signaling. This 15-gene-based signature will be used to study dormancy in patient samples. Additionally, dormant cells will be used in cytoto ...

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model

P74 | AUTOMATED PANEL-AGNOSTIC FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA USING QUALITY CONTROL-AWARE MACHINE LEARNING (244 Online Views)

First match: ... ition depth, panel composition, and fluorochrome configuration. The aim of this study was to evaluate automated MRD detection using a quality control (QC)–aware, pan ...

E. Akar1, M. Baysal1, S. Cakmak1, S. Akpinar1, B. Turgut1

1 Hematology Department, Tekirdag Namik Kemal University Hospital, Turkey
Multiple Myeloma Minimal residual disease Quality Control

P73 | TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTRÖM MACROGLOBULINEMIA IN A REAL WORLD COHORT (279 Online Views)

First match: ... ging System for WM (MSS-WM).Methods. We performed a retrospective single center study including patients diagnosed with WM and followed at Ankara University between ...

U. Calis1, S. Yuksel2, M. K. Yuksel1, P. Topcuoglu1, I. Kuzu2, O. Arslan1, M. Ozcan1, T. Demirer1, S. Kocak Toprak1, M. Beksac3, G. Cengiz Seval1

1 Department of Hematology, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Department of Hematology Istinye University, Ankara Liv Hospital, Turkey
Waldenström macroglobulinemia Real-world Practice

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (237 Online Views)

First match: ... e, we compared data from REALiTEC, an international retrospective observational study of teclistamab use outside of clinical trials, with pooled data from LocoMMotio ...

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (276 Online Views)

First match: ... er pt experienced G4 neutropenia on C1D15 not resolved within 7 days of holding study medication; G4 neutropenia recovered by C2D15 after 2 filgrastim doses (C1D15 a ...

C. Mo1, C. Gasparetto2, C. Costa2, A.J. Cowan3, T. Mark4, Y. Chai4, T. Kashyap4, J. Katz5, M. Amatangelo5, P.G. Richardson1

1 Dana-Farber Cancer Institute, Boston, USA
2 Duke Cancer Institute, Durham, USA
3 University of Washington, Seattle, USA
4 Karyopharm Therapeutics, Newton, USA
5 Bristol Myers Squibb, Princeton, USA
Multiple Myeloma RRMM STOMP trial

P62 | INITIAL EXPERIENCE WITH IDECABTAGENE VICLEUCEL IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA: CASE SERIES IN A TERTIARY CARE HOSPITAL (230 Online Views)

First match: ... patients treated with ide-cel at our center.Methods. Retrospective descriptive study of 3 patients with refractory MM treated with ide-cel in 2024. Data collected: ...

L. Piquer Monsonis1, A. Pérez Montaña1, J.M. Sánchez Raga1, A. Sampol Mayol1, M. Galí Sampol1, R. Ferrero Guillén1, E. Serrasoles Alemany1, M. Remezal Serrano1, A. Alonso Carballo1, S. Montolio Chiva1, P. Gómez Fernández1, J. Domínguez Esteve2, A. Horrillo Orejudo2

1 Department of Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain
2 Hospital Comarcal de Inca, Spain
BCMA Decabtagene vicleucel Multiple Myeloma

P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS (304 Online Views)

First match: ... MMy (NCT05879757) is an ongoing, prospective, non-interventional, observational study of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% in adult p ...

E. Kastritis1, S. Sánchez-Ramón2, A.G. Szabo3, B. Machalinski4, A. Pérez-Montaña5, J. Chen6, B. Mc Coy7, M. Kamieniak6, S. Wietek7

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
2 Department of Clinical Immunology, Institute of Laboratory Medicine, Hospital Clínico San Carlos, Complutense University of Madrid, Spain
3 Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark
4 Department of Hematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
5 Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
6 Takeda Development Center Americas, Inc, Cambridge, USA
7 Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Multiple Myeloma HyMMy Trial Secondary immunodeficiency

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (317 Online Views)

First match: ... in pts with previously treated AL amyloidosis.Methods. This ongoing open-label study aims to enroll 30 pts ≥18 yrs with histologic diagnosis of systemic AL amyloido ...

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial

P68 | BIOPSY SPECIFIC CHARACTERISTICS ARE IMPORTANT IN DETECTING AMYLOID IN PATIENTS WITH AMYLOIDOSIS (227 Online Views)

First match: ... e associated with a CR negative stain in fat aspirations. In this single-center study we investigated whether biopsy-specific characteristics also affect sensitivity ...

F.G. Weverling1, A. Vinkenborg1, R.J. Leguit2, M.C. Minnema1

1 Department of Hematology, University Medical Center Utrecht, The Netherlands
2 Department of Pathology, University Medical Center Utrecht, The Netherlands
AL amyloidosis Multiple Myeloma CR-staining

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (289 Online Views)

First match: ... 3 patients were mayo stage 3 or 4. All patients had impaired renal function at study entry, including 4 with eGFR <30 mL/min, two them were dialysis dependent. P ...

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab
1 - 25 of 53 items 1 2 3 > >> 
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online